Indinavir

CAS No:
150378-17-9 Category:
  • #LGM Pharma is a Indinavir CAS# 150378-17-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 150378-17-9
  • AHFC code: 08:18.08.08
  • Synonyms: Compound J Indinavir sulfate
  • ATC Code: J05AE02
  • Chemical Formula: C20H28O2
  • Molecular Weight: 613.7895
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00224 (APRD00069)
  • SMILES: CC(C)(C)NC(=O)[C,,H]1CN(CC2=CN=CC=C2)CCN1C[C,,H](O)C[C,,H](CC1=CC=CC=C1)C(=O)N[C,,H]1[C,H](O)CC2=CC=CC=C12
  • InChl: CBVCZFGXHXORBI-PXQQMZJSSA-N
  • PubChem: 5362440
  • IUPAC: (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide

Additional Details

Indication:
Indinavir is an antiretroviral drug for the treatment of HIV infection.
Pharmacodynamics:
Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mode of Action:
Indinavir inhibits the HIV viral protease enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Metabolism:
Hepatic. Seven metabolites have been identified, one glucuronide conjugate and six oxidative metabolites. In vitro studies indicate that cytochrome P-450 3A4 (CYP3A4) is the major enzyme responsible for formation of the oxidative metabolites.
Toxicity:
Symptoms of overdose include myocardial infarction and angina pectoris.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos